Xenon Pharmaceuticals XENE Fair Value Of Stock Options And Warrants Exercised On A Cashless Basis
Fair Value Of Stock Options And Warrants Exercised On A Cashless Basis at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept xene:FairValueOfStockOptionsAndWarrantsExercisedOnACashlessBasis.
The official record: Xenon Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's fair value of stock options and warrants exercised on a cashless basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's fair value of stock options and warrants exercised on a cashless basis?
- Xenon Pharmaceuticals (XENE) reported fair value of stock options and warrants exercised on a cashless basis of $5.25M in Q4 2025.
- How has Xenon Pharmaceuticals's fair value of stock options and warrants exercised on a cashless basis changed year-over-year?
- Xenon Pharmaceuticals's fair value of stock options and warrants exercised on a cashless basis increased by 152.8% year-over-year, from $2.08M to $5.25M.
- What is the long-term trend for Xenon Pharmaceuticals's fair value of stock options and warrants exercised on a cashless basis?
- Over 2 years (2023 to 2025), Xenon Pharmaceuticals's fair value of stock options and warrants exercised on a cashless basis has grown at a 100.0% compound annual growth rate (CAGR), from $5.25M to $21M.
- What does fair value of stock options and warrants exercised on a cashless basis mean?
- This metric quantifies the fair value of equity instruments exercised through cashless methods, where the company settles the exercise price by withholding shares rather than receiving cash. While this does not result in a direct cash inflow, it represents the dilution of existing shareholders and the settlement of compensation obligations. It is a critical component for analyzing the company's total equity-based compensation and capital structure changes.